ClinicalTrials.gg
CompletedNCT00259779SPACEUpdated Jan 24, 2011

Comparison Between Symbicort® and Prednisolone in COPD

A Phase 3 interventional study of budesonide/formoterol and Prednisolone in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 37 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
19th of 43
120 · median 99
Started
2005
with 1 other
Phase 3
15 of 43
1 open now
Registered
3rd of 43
by date
Lead sponsor
10 of 43
AstraZeneca

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 19th largest by planned enrollment, is one of 2 that started in 2005, is one of 15 in phase 3, and was the 3rd registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

To assess if Symbicort forte Turbuhaler (during two weeks) is as effective as an oral course of prednisolone + Oxis Turbuhaler (during two weeks) for the treatment of an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with and an acute exacerbation
  • After the acute treatment a simple pulmonary function test shows a value of 30%-60% of the predicted normal value.
  • Patients, who, based on the clinical examination after the initial acute treatment, are candidates for a course of oral for the treatment of acute symptoms due to chronic obstructive pulmonary disease

Exclusion criteria

Exclusion Criteria:

  • Diagnosis/history of asthma
  • Oxygen uptake (saturation) is \<92% after the initial acute treatment
  • A requirement for regular use of oxygen therapy
  • Regular treatment with any inhaled >1 000 µg/day at study entry

Additional inclusion and exclusion criteria will be evaluated by the investigator

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
120 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in one second (FEV1)

Secondary outcomes

  1. Number of patients with treatment failures

  2. Time to first exacerbation

  3. Number of patients developing an exacerbation

  4. Diary cards

  5. Quality of Life

  6. - Adverse Events (AEs)

  7. Serious Adverse Events (SAEs) and Discontinuations due to AEs

  8. Variables will be assessed before and over the 2+12 weeks treatment period

07

Study locations

37 sites
  • Research Site
    Aalbaek, Denmark
  • Research Site
    Aalborg, Denmark
  • Research Site
    Christiansfeld, Denmark
  • Research Site
    Erfurt, Denmark
  • Research Site
    Norager, Denmark
  • Research Site
    Oksbol, Denmark
  • Research Site
    Saeby, Denmark
  • Research Site
    Lohja, Finland
  • Research Site
    Pietarsaari, Finland
  • Research Site
    Porvoo, Finland
  • Research Site
    Tammisaari, Finland
  • Research Site
    Berlin, Germany
  • Research Site
    Leipzig, Germany
  • Research Site
    Marburg, Germany
  • Research Site
    Fredrikstad, Norway
  • Research Site
    Harstad, Norway
  • Research Site
    Molde, Norway
  • Research Site
    Oslo, Norway
  • Research Site
    Straume, Norway
  • Research Site
    Akersberga, Sweden
  • Research Site
    Alingsas, Sweden
  • Research Site
    Atvidaberg, Sweden
  • Research Site
    Borlange, Sweden
  • Research Site
    Goteborg, Sweden
  • Research Site
    Hollviken, Sweden
  • Research Site
    Kilafors, Sweden
  • Research Site
    Limhamn, Sweden
  • Research Site
    Lindesberg, Sweden
  • Research Site
    Lulea, Sweden
  • Research Site
    Malmo, Sweden
  • Research Site
    Motala, Sweden
  • Research Site
    Sigtuna, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Trosa, Sweden
  • Research Site
    Tumba, Sweden
  • Research Site
    Uppsala, Sweden
  • Research Site
    Örebro, Sweden
08

References and documents

Publications

  • Stallberg B, Selroos O, Vogelmeier C, Andersson E, Ekstrom T, Larsson K. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res. 2009 Feb 19;10(1):11. doi: 10.1186/1465-9921-10-11. PubMed 19228428 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2005
First posted
Dec 1, 2005
Start
Sep 2005
CompletionActual
Jul 2007
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00259779
Lead sponsor
AstraZeneca
First posted
Dec 1, 2005
Start date
Sep 2005
Completion
Jul 2007
Last update
Jan 24, 2011

Study contacts

AstraZeneca Symbicort Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol · Prednisolone

Start the discussion